Synthetic biology devices and circuits for RNA-based ‘smart vaccines’: a propositional review
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Nucleic acid vaccines have been gaining attention as an alternative to the standard attenuated pathogen or protein based vaccine. However, an unrealized advantage of using such DNA or RNA based vaccination modalities is the ability to program within these nucleic acids regulatory devices that would provide an immunologist with the power to control the production of antigens and adjuvants in a desirable manner by administering small molecule drugs as chemical triggers. Advances in synthetic biology have resulted in the creation of highly predictable and modular genetic parts and devices that can be composed into synthetic gene circuits with complex behaviors. With the recent advent of modified RNA gene delivery methods and developments in the RNA replicon platform, we foresee a future in which mammalian synthetic biologists will create genetic circuits encoded exclusively on RNA. Here, we review the current repertoire of devices used in RNA synthetic biology and propose how programmable 'smart vaccines' will revolutionize the field of RNA vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“, tetracycline-controlled transactivator: tTA [65] and reverse tetracycline-controlled transactivator: rtTA [66]) are arguably the most commonly used regulatory devices for creating synthetic gene circuits on DNA.”
BackgroundNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“The innate immune response is particularly problematic when carriers such as cationic liposomes or polymers are used for the delivery of mRNAs into cells (for a recent review on nucleic acid delivery methods see [32]).”
BackgroundKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662 · cited 1×
“However, the induction of an innate immune response is still a major concern in cells that are known to possess high levels of PRRs, such as epithelial cells, as shown by us and others [33,34].”
BackgroundTranscriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“, tetracycline-controlled transactivator: tTA [65] and reverse tetracycline-controlled transactivator: rtTA [66]) are arguably the most commonly used regulatory devices for creating synthetic gene circuits on DNA.”
BackgroundmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · cited 3×
“While RNA-based vaccines are completely synthetic, provide compositional control and cost five- to ten-times less to manufacture than protein-based therapeutics [24], the creation of effective and universal nucleic acid-based prophylactic solutions is still challenging.”
BackgroundMethodInfluentialThe alphaviruses: gene expression, replication, and evolution.
Strauss, J. H., & Strauss, E. G. (1994) · Microbiological Reviews · doi:10.1128/mmbr.58.3.491-562.1994 · Cited by 2,221
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 1×
“Modified mRNA Typically > ~500 nt Medium ~4 weeks Low No [36,39,40]”
BackgroundThe second wave of synthetic biology: from modules to systems
Purnick, P. E. M., & Weiss, R. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2698 · Cited by 1,181 · cited 1×
“This process typically involves the top-down decomposition of the high-level behavior (sensing–processing–actuation) of a genetic circuit followed by the physical implementation of the circuit via bottom-up assembly of categorized or novel biological devices with standardized functions [14,15].”
BackgroundSelf-citationBanaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902 · cited 3×
“When a vaccinia virus harboring a fusion protein between DDf and the cytokine IL-2 was systemically delivered to tumor-bearing mice, administration of Shield-1 to the mouse led to stabilization of IL-2 and a reduction in the size of the tumor [128].”
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741 · cited 1×
“recently showed that gene expression from alphaviral RNA replicons can last for at least 7 weeks in vivo when replicon RNA was packaged in lipid nanoparticles and injected into the muscle of mice for vaccination [44].”
BackgroundExpression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733 · cited 2×
“Modified mRNA Typically > ~500 nt Medium ~4 weeks Low No [36,39,40]”
BackgroundIncorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356
Control of mammalian translation by mRNA structure near caps
Babendure, J. R., Babendure, J. L., Ding, J.-H., & Tsien, R. Y. (2006) · RNA · doi:10.1261/rna.2309906 · Cited by 339
Efficient generation of human iPSCs by a synthetic self-replicative RNA
Yoshioka, N., Gros, E., Li, H.-R., Kumar, S., Deacon, D. C., Maron, C., Muotri, A. R., Chi, N. C., Fu, X.-D., Yu, B. D., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.001 · Cited by 312 · cited 1×
“Other groups have successfully used alphaviral replicons for the purpose of induced pluripotent stem cell generation [45] or even in vivo artificial miRNA delivery [46] demonstrating their potential as a broad-purpose gene-expression vector.”
Ferre-D'Amare, A. R., & Scott, W. G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003574 · Cited by 205 · cited 1×
“Furthermore, RNA-based devices can be versatile compared to DNA as they can carry the information of a protein output as well as form 3D structures with enzymatic activities [48] or even rearrange into higher-order assemblies [49].”
BackgroundVaccination with Messenger RNA (mRNA)
Pascolo, S. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-72167-3_11 · Cited by 126 · cited 1×
“Unmodified mRNA Typically > ~500 nt Low ~1 week High No [25,141,142]”
BackgroundModel-Driven Engineering of Gene Expression from RNA Replicons
Beal, J., Wagner, T. E., Kitada, T., Azizgolshani, O., Parker, J. M., Densmore, D., & Weiss, R. (2015) · ACS Synthetic Biology · doi:10.1021/sb500173f · Cited by 38 · cited 1×
“More recently, to facilitate the use of alphaviral replicons as a platform for synthetic gene circuit engineering, our group created a mathematical model for Alphavirus gene-expression kinetics using high-density time course data [47].”
MethodSelf-citation
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
“Future work may demonstrate the benefits of using m1Ψ-modified mRNA for medical applications such as genetic reprogramming, stem cell differentiation, protein replacement therapy, vaccination, passive immunoprophylaxis (vectored-antibody expression), and other advanced therapeutic goals [36].”
BackgroundSelf-citationAn Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Antibiotic-free selection in biotherapeutics: Now and forever
Mignon, C., Sodoyer, R., & Werle, B. (2015) · Pathogens · doi:10.3390/pathogens4020157 · Cited by 87
“is the use of RNA-based nucleic acid vaccination [101,102].”
Background
Metadata
- Authors
- Andries, O., Kitada, T., Bodner, K., Sanders, N. N., & Weiss, R.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2015-01-07
- Volume
- 14
- Issue
- 2
- Pages
- 313-331
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2153554039
- Cited by
- 49
- References
- 20
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.